secwatch.observer — SEC 8-K summary
======================================

Issuer:     HOOKIPA Pharma Inc. (HOOK)
CIK:        0001760542
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0001558370-22-013170
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HOOKIPA Q2 2022 revenue $2.7M, net loss $16.4M; FDA accepts IND for HB-300, HB-200 Phase 2 underway
--------------------------------------------------------------------------------

- Revenue $2.7M, down from $5.4M YoY due to lower cost reimbursements from Gilead collaboration.
- Net loss $16.4M versus $17.2M in Q2 2021; R&D expenses decreased to $16.1M from $19.6M.
- Cash, equivalents and restricted cash $118.9M at June 30, 2022, up from $66.9M at Dec 31, 2021.
- FDA accepted IND for HB-300 (metastatic castration-resistant prostate cancer) and Drug Master File for platform.
- HB-200 Phase 1 met all endpoints; Phase 2 started; initial data with pembrolizumab expected H2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1760542/000155837022013170/0001558370-22-013170-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1760542/000155837022013170/hook-20220811x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-013170

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer